|Proteome Sciences plc -- UK Stock|| |
GBp 3.1 0.03 0.98%
VP of Bus. Devel. - USA
Mr. Glenn Barney is Vice President Business Development, USA of Proteome Sciences PLC. Glenn brings over 25 years of sales and business development experience with global life sciences companies, with strong biomarker focus. He was formerly VP Business Development at NextGen Sciences Inc. and held senior positions at Decision Biomarkers and Parkin Elmer Inc
VP Since 2011
44 19 3286 5065 http://www.proteomics.com
Barney holds a BA in Biology from Boston University..
The company has return on total asset (ROA)
of (20.17) %
which means that it has lost $20.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (16.4) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 8.93 M in total debt. Proteome Sciences plc has Current Ratio of 0.38 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Proteome Sciences plc, a life sciences company, engages in the research and development of biomarkers. Proteome Sciences plc (PRM) is traded on London Stock Exchange in UK. It is located in Cobham, KT EP and employs 35 people.